Tvardi Therapeutics Reports Positive Interim Phase 2 HCC Data and Encouraging IPF Post-Hoc Analysis
TVRD sits 24% above its 52-week low of $3.74 on light trading volume (0.1× avg).
Summary
Tvardi Therapeutics provided an updated corporate presentation detailing positive interim Phase 1b/2 results for TTI-101 in hepatocellular carcinoma (HCC) and encouraging post-hoc analysis from its TTI-101 idiopathic pulmonary fibrosis (IPF) trial, alongside updates on its TTI-109 prodrug.
Key Events · Product Development and Regulatory · TVRD
-
Positive Interim HCC Data
The TTI-101 Phase 1b/2 trial in hepatocellular carcinoma (HCC) demonstrated a 92% disease control rate and 33% objective response rate, which compares favorably to third-party trials.
-
Encouraging IPF Post-Hoc Analysis
A post-hoc analysis of the TTI-101 idiopathic pulmonary fibrosis (IPF) trial indicated greater declines in fibrosis score and IL-6 levels, and an increase in FVC among treated patients, despite initial trial challenges.
-
TTI-109 Prodrug Advancement
The company is progressing TTI-109, a prodrug designed to enhance TTI-101 delivery, with Phase 1 healthy volunteer data anticipated in the first half of 2026.
-
Cash Runway Update
Tvardi Therapeutics reported $36.5 million in cash and equivalents as of September 30, 2025, providing an anticipated cash runway into Q4 2026.
Analysis · TVRD · Life Sciences
The updated corporate presentation highlights significant progress in Tvardi's clinical pipeline. The interim Phase 1b/2 data for TTI-101 in hepatocellular carcinoma (HCC) shows a high disease control rate (92%) and objective response rate (33%), which compares favorably to existing therapies and suggests strong potential in an area of high unmet need. While the initial TTI-101 idiopathic pulmonary fibrosis (IPF) trial faced challenges, the detailed post-hoc analysis revealed positive trends in fibrosis reduction, IL-6 decline, and FVC improvement, indicating a potential therapeutic effect. These clinical advancements, particularly the promising HCC data, are crucial for a micro-cap biotech and could significantly impact the company's valuation and future development strategy. Investors should monitor the upcoming topline results for the Phase 2 HCC trial in 1H 2026.
At the time of this filing, TVRD was trading at $4.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $43.4M. The 52-week trading range was $3.74 to $43.65. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.